000 04859cam a2200445Ii 4500
999 _c96145
_d96145
001 96145
003 ES-MaUEC
005 20230102112740.0
006 m o d
007 cr cnu|||unuuu
008 170608s2017 ne a o 001 0 eng d
020 _a9400776756
_q(electronic bk.)
020 _a9789400776753
_q(electronic bk.)
020 _z9789400776746
_q(print)
020 _z9789400776760
_q(print and electronic bundle)
040 _aGW5XE
_cGW5XE
_dYDX
_dUAB
_dAZU
_dESU
_dUPM
_dIOG
_dCOO
_dMERER
_dVT2
_dAUD
_dNJR
_dJG0
_dU3W
_dES-MaUEC
_bspa
050 4 _aRC847
_b.B566 2017 EB
066 _c(S
245 0 0 _aBiomarkers in liver disease
_cVinood B. Patel, Victor R. Preedy, editors.
264 1 _aDordrecht, Netherlands
_bSpringer
_c2017.
300 _a1 recurso en línea
_bilustraciones (algunas a color)
336 _aTexto
_btxt
_2rdacontent
337 _aelectrónico
_bc
_2rdamedia
338 _arecurso electrónico
_bcr
_2rdacarrier
347 _atext file
_bPDF
490 0 _aBiomarkers in disease: methods, discoveries and applications
_x2542-3657
500 _aIncluye índice
500 _aSpringerLink
520 3 _aThere are numerous types of liver disease that may be due to toxic agents (such as alcohol or drugs), infectious agents including viruses, congenital conditions and even poor dietary patterns. It has been suggested that there are over 100 different types. As the consequences of liver failure can be devastating it is important that appropriate diagnosis and monitoring is carried out. Much of this characterisation entails the use of biological indicators, i.e biomarkers. Biomarkers in Liver Disease embraces a holistic approach by combining detailed information on different conditions that affect the liver and the use of biomarkers. Biomarkers are described in terms of conventional, new and emerging analytes, techniques, platforms and applications. It covers the latest knowledge, trends and innovations. New platforms are described which combine advances in biomedical sciences, physics, computing and chemistry.
588 0 _aOnline resource; title from PDF title page (SpringerLink, viewed June 8, 2017).
988 _aEBOOK, EBSPRINGER_2017D
650 7 _2embne
_9676621
_aVesícula biliar
_xEnfermedades
650 7 _2embne
_aGastroenterología
_9141308
700 1 _aPatel, Vinood B.,
_eeditor literario
_985991
700 1 _aPreedy, Victor R.,
_eeditor literario
_985990
856 4 0 _uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-94-007-7675-3
_zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
880 0 _6505-00
_aLiver biomarkers and their applications to nutritional interventions in animal studies -- AST-to-platelet ratio index (APRI) as marker in liver disease.-Inflammatory biomarkers in ascites -- Biomarkers for hepatocellular carcinoma in East Asia -- Liver disease and acylcarnitines as mechanistic biomarkers.-Type VI Collagen: Biological Functions and its Neo-epitope as Hepatic Fibrosis Biomarker -- Fibrinogen α-chain as a serum marker of liver disease -- Monocyte chemotactic protein-1 (cytokine, receptors,and gene polymorphisms) in hepatitis -- Biomarkers for Recurrence of Hepatocellular Carcinoma.-Graft-derived cell-free DNA as a biomarker in liver transplantation -- Serum sialic acid as a biomarker in liver disease -- CD133 and EpCAM as Biomarkers in Liver Diseases -- Traditional markers in liver disease -- Biomarkers of extracellular matrix remodeling in liver diseases -- Squamous Cell Carcinoma Antigen- Immunoglobulin M (SCCA-IgM) as biomarker in liver disease: biological aspects and clinical applications -- microRNA-155 and microRNA-196b in hepatitis C virus infection -- Immunological biomarkers in liver transplantation -- Phosphatidylethanol and alcohol use in liver disease patients -- Interaction of sialyltransferases, sialidases and sialic acids in liver diseases and applications to biomarker discovery -- Biomarkers to monitor graft function following liver transplantation -- YKL-40 as a biomarker of liver diseases -- Peripheral venous, portal venous, hepatic venous, arterial and intrahepatic cytokine levels as biomarkers and functional correlations -- Histological Biomarkers of Non-Alcoholic Fatty Liver Disease -- Vascular cell adhesion molecule-1 (vcam-1) expression in liver disease -- Bilirubin as a biomarker in liver disease -- Hydroxyproline as a biomarker in liver disease -- Genetic biomarkers of paracetamol-induced acute liver failure -- PNPLA3 polymorphism and Nonalcoholic Fatty Liver Disease -- Hepascore and it's application to liver disease -- Model for End-Stage Liver Disease (MELD) Score as a Biomarker -- Biomarkers in focus: Alanine Aminotransferase -- PTX3 as a biomarker of liver disease.
942 _2lcc
_cLE
998 _b02/2018
_dz
_e-
_zSI